Voyager Therapeutics (NASDAQ:VYGR) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Voyager Therapeutics (NASDAQ:VYGR) from a sell rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.

Several other research analysts have also weighed in on VYGR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Friday, October 9th. HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $1.99 on Friday. Voyager Therapeutics has a one year low of $1.68 and a one year high of $5.48. The business has a 50-day moving average price of $2.52 and a two-hundred day moving average price of $3.40.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.02. The company had revenue of $0.61 million for the quarter, compared to the consensus estimate of $6.35 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. As a group, analysts anticipate that Voyager Therapeutics will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in the company. Spark Investment Management LLC bought a new position in Voyager Therapeutics during the second quarter valued at approximately $47,000. Ieq Capital LLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth $48,000. The Manufacturers Life Insurance Company bought a new position in shares of Voyager Therapeutics during the 2nd quarter valued at $61,000. Chase Investment Counsel Corp acquired a new stake in shares of Voyager Therapeutics in the 1st quarter valued at $76,000. Finally, DLD Asset Management LP acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at $70,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.